Related references
Note: Only part of the references are listed.Review article: the antimicrobial effects of rifaximin on the gut microbiota
H. L. DuPont
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Review article: the potential mechanisms of action of rifaximin in the management of inflammatory bowel diseases
R. B. Sartor
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women
Shin Fukudo et al.
GASTROENTEROLOGY (2016)
Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD
C. Casen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Altered Colonic Bacterial Fermentation as a Potential Pathophysiological Factor in Irritable Bowel Syndrome
Tamar Ringel-Kulka et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2015)
Burden of Gastrointestinal, Liver, and Pancreatic Diseases in the United States
Anne F. Peery et al.
GASTROENTEROLOGY (2015)
Irritable Bowel Syndrome A Clinical Review
William D. Chey et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome
Evangelos Giamarellos-Bourboulis et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2015)
Heme oxygenase-1 protects rat liver against warm ischemia/reperfusion injury via TLR2/TLR4-triggered signaling pathways
Han-Fei Huang et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy
N. Kimer et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials
P. Schoenfeld et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Review article: the economic impact of the irritable bowel syndrome
C. Canavan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
The Effect of Fiber Supplementation on Irritable Bowel Syndrome: A Systematic Review and Meta-analysis
Paul Moayyedi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Effect of Antidepressants and Psychological Therapies, Including Hypnotherapy, in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2014)
Rifaximin Is Safe and Well Tolerated for Long-term Maintenance of Remission From Overt Hepatic Encephalopathy
Kevin D. Mullen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Pregnane X receptor agonists enhance intestinal epithelial wound healing and repair of the intestinal barrier following the induction of experimental colitis
Joshua Terc et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Rifaximin Alters Intestinal Bacteria and Prevents Stress-Induced Gut Inflammation and Visceral Hyperalgesia in Rats
Dabo Xu et al.
GASTROENTEROLOGY (2014)
A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
Klara Garsed et al.
GUT (2014)
In vitro activity of rifaximin against isolates from patients with small intestinal bacterial overgrowth
Aikaterini Pistiki et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Uncomplicated Diverticular Disease: Innate and Adaptive Immunity in Human Gut Mucosa before and after Rifaximin
Rossella Cianci et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints
E. M. M. Quigley et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Use of Rifamycin Drugs and Development of Infection by Rifamycin-Resistant Strains of Clostridium difficile
Jamie S. Huang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Update on rifampin, rifabutin, and rifapentine drug interactions
Anne M. Baciewicz et al.
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Eluxadoline Benefits Patients With Irritable Bowel Syndrome With Diarrhea in a Phase 2 Study
Leonard S. Dove et al.
GASTROENTEROLOGY (2013)
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Magnus Simren et al.
GUT (2013)
Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
Jasmohan S. Bajaj et al.
PLOS ONE (2013)
Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months
P. Meyrat et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
Stacy B. Menees et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis
Rebecca M. Lovell et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
The Prevalence of Overgrowth by Aerobic Bacteria in the Small Intestine by Small Bowel Culture: Relationship with Irritable Bowel Syndrome
Emmannouil Pyleris et al.
DIGESTIVE DISEASES AND SCIENCES (2012)
Irritable bowel syndrome: Physicians' awareness and patients' experience
Linda Bjork Olafsdottir et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis
Sanjin Alajbegovic et al.
SYSTEMATIC REVIEWS (2012)
Physical Activity Improves Symptoms in Irritable Bowel Syndrome: A Randomized Controlled Trial
Elisabet Johannesson et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Effects of Rifaximin Treatment and Retreatment in Nonconstipated IBS Subjects
Mark Pimentel et al.
DIGESTIVE DISEASES AND SCIENCES (2011)
Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS
Derek Yu et al.
GUT (2011)
Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review
Alexander C. Ford et al.
JOURNAL OF GASTROENTEROLOGY (2011)
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation.
Mark Pimentel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
High-dose rifaximin treatment alleviates global symptoms of irritable bowel syndrome
John Jolley
CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY (2011)
Pretreatment of Epithelial Cells with Rifaximin Alters Bacterial Attachment and Internalization Profiles
Eric L. Brown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Bile Acids Improve the Antimicrobial Effect of Rifaximin
Charles Darkoh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei
Zhi-Dong Jiang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome
Derrick K. Ong et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2010)
Therapeutic Role of Rifaximin in Inflammatory Bowel Disease: Clinical Implication of Human Pregnane X Receptor Activation
Jie Cheng et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Pathogenesis of IBs: role of inflammation, immunity and neuroimmune interactions
Lena Ohman et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome - results of two randomized, placebo-controlled studies
D. A. Drossman et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Efficacy of 5-HT3 Antagonists and 5-HT4 Agonists in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Small Intestinal Bacterial Overgrowth in Irritable Bowel Syndrome: Systematic Review and Meta-analysis
Alexander C. Ford et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Irritable bowel syndrome: A 10-yr natural history of symptoms and factors that influence consultation behavior
Alexander C. Ford et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome
K. Matsueda et al.
DIGESTION (2008)
Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis
Qian Jiang et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2008)
T1390 Rifaximin for the Treatment of Diarrhea-Associated Irritable Bowel Syndrome: Short Term Treatment Leading to Long Term Sustained Response
Anthony Lembo et al.
GASTROENTEROLOGY (2008)
Systemic pharmacokinetics of rifaximin in volunteers with shigellosis
David N. Taylor et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis
Alexander C. Ford et al.
BMJ-BRITISH MEDICAL JOURNAL (2008)
Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS
Janet Yang et al.
DIGESTIVE DISEASES AND SCIENCES (2008)
The effect of multiple-dose, oral rifaximin on the pharmacokinetics of intravenous and oral midazolam in healthy volunteers
Helen S. Pentikis et al.
PHARMACOTHERAPY (2007)
Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome
M. Thabane et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2007)
The cognitive behavioural model of irritable bowel syndrome: a prospective investigation of patients with gastroenteritis
Meagan J. Spence et al.
GUT (2007)
The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects
Anna Kassinen et al.
GASTROENTEROLOGY (2007)
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Iris Posserud et al.
GUT (2007)
Absence of effect of oral rifaximin on the pharmacokinetics of ethinyl estradiol/norgestimate in healthy females
Carol Braun Trapnell et al.
ANNALS OF PHARMACOTHERAPY (2007)
The effect of a nonabsorbed oral antibiotic (Rifaximin) on the symptoms of the irritable bowel syndrome - A randomized trial
Mark Pimentel et al.
ANNALS OF INTERNAL MEDICINE (2006)
Postinfectious irritable bowel syndrome - A meta-analysis
Heather A. Halvorson et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes
Simon P. Dunlop et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: Systematic review of clinical trials and post-marketing surveillance data
Lin Chang et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Functional bowel disorders
George F. Longstreth et al.
GASTROENTEROLOGY (2006)
Psychosocial aspects of the functional gastrointestinal disorders
Rona L. Levy et al.
GASTROENTEROLOGY (2006)
A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence
AI Sharara et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic
C Scarpignato et al.
DIGESTION (2006)
Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome
SD Kuiken et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth
EC Lauritano et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2005)
CXC and CC chemokine expression in inflamed and noninflamed pelvic ileal pouch tissue
U Helwig et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2004)
Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis
S Fiorucci et al.
DIGESTION (2002)
Rifaximin: A nonabsorbed antimicrobial as a new tool for treatment of travelers' diarrhea
R Steffen
JOURNAL OF TRAVEL MEDICINE (2001)
In vitro activity and fecal concentration of rifaximin after oral administration
ZD Jiang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2000)
Share Paper
